1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Addex founder launches first Swiss spin-out from Merck Serono

 
• By Eleanor Malone

François Conquet, the co-founder and former CEO of Addex Therapeutics, is to head a new company, Prexton Therapeutics, which is to be spun out of the soon-to-be-closed Geneva operations of Merck Serono.

François Conquet, the co-founder and former CEO of Addex Therapeutics, is to head a new company, Prexton Therapeutics, which is to be spun out of the soon-to-be-closed Geneva operations of Merck Serono.

Like Addex, Prexton will be focused on CNS. More specifically, it will work with preclinical assets from Merck Serono which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

More from Therapeutic Category